Anti-HBs×CD3(SCG Cell Therapy)

N/A

Report date: 2026/03/19 17:16:05

First In Class

Base Information

Drug NameAnti-HBs×CD3(SCG Cell Therapy)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Anti-HBsAg

TargetsT cell surface glycoprotein CD3Hepatitis B Surface Antigens

Therapy Area/IndicationsHepatitis B

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySingapore

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSCG Cell Therapy Pte Ltd

China Registration ClassN/A

Develop Information

Active CompaniesSCG Cell Therapy Pte Ltd

Inactive CompaniesN/A

Active IndicationsHepatitis B

Inactive IndicationsN/A

Other Information

ATC CodeN/A